Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system. Since 1999, Cypress has received multiple FDA approvals, including Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia. Cypress' currently marketed product is Savella. Development-stage assets include CYP-1020 for cognitive impairment in schizophrenia, as well as AVISE-SLESM, a lupus diagnostic testing service. AVISE-SLESM is included in the Company's personalized medicine services business, which the Company recently announced it intends to sell or cease operating by the end of the third quarter of 2010.
| Website | http://www.cypressbio.com |
| Revenue | $17.2 million |
| Employees | View employees |
| Address | 4350 Executive Dr Ste 325, San Diego, California 92121, US |
| Phone | +1 619-452-2323 |
| Industry | Medical Testing & Clinical Laboratories, Healthcare |
| Competitors | Novartis, Pfizer, Takeda, Alkermes, Lundbeck, Neurocrine Biosciences, Intra-Cellular Therapies, Otsuka (Philippines) Pharmaceutical, Inc., Lilly India, Aptinyx Inc. +39 more (view full list) |
| SIC | SIC Code 80 Companies, SIC Code 283 Companies, SIC Code 807 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 62 Companies, NAICS Code 3254 Companies, NAICS Code 339 Companies, NAICS Code 33 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 621 Companies, NAICS Code 325 Companies |
Looking for a particular Cypress Bioscience , Inc. employee's phone or email?
Cypress Bioscience , Inc. Questions
The Cypress Bioscience , Inc. annual revenue was $17.2 million in 2026.
Cypress Bioscience , Inc. is based in San Diego, California.
The NAICS codes for Cypress Bioscience , Inc. are [62, 3254, 339, 33, 32541, 32, 621, 325].
The SIC codes for Cypress Bioscience , Inc. are [80, 283, 807, 28].
Related Companies
